Categories: NewsPharmaceutical

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference.

Investor Conference Details:

H.C. Wainwright 27th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York City
Conference Dates: September 8-10, 2025
Presentation Date: September 10, 2025 at 10:30 A.M. ET
One on one meeting availability: September 10, 2025

Institutional investors interested in scheduling an in-person one-on-one meeting should contact their institutional sales rep or register for the conference via this LINK.   

A webcast of the presentation will be available on the Events and Presentations pages of Pelthos’ website at https://pelthos.com. Archived replays will be available for 90 days following the event.

Investor Summit Group Q3 Virtual Conference
Location: Virtual
Conference Dates: September 16-17, 2025

To register for this event please visit this LINK.

About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Pelthos Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh / Rachel Kessler
pelthos@kwmcommunications.com
(914) 315-6072

Staff

Recent Posts

Lightera Advances Fiber-integrated Temperature Feedback for Safer Laser-based Medical Procedures

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- BiOS - Hall D Booth #8430, Photonics West Hall…

24 hours ago

DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

1 day ago

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

1 day ago

Instinct Science Acquires ScribbleVet to Deliver the Next Generation of Intelligent-Native Veterinary Practice Management Software

The combination redefines PIMS by embedding AI, workflow, and clinical intelligence into a single system…

1 day ago

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

1 day ago